Vascepa (Icosapent Ethyl) Patent Expiration, LOE Window & CMS Spending
Vascepa (Icosapent Ethyl) by Amarin Ireland: FDA Orange Book LOE 2033-06-28, 12 AB generics, $771.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amarin Ireland |
| FDA Application & Pathway | N202057 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-06-28 |
| Orange Book Patents (*PED Extensions) | 61 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $771.6M |
| 2024 Medicare Part D Spend | $724.2M |
| 2024 Medicaid Spend | $47.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |